López-Marte Paola, Soto-González Alondra, Ramos-Tollinchi Lizzie, Torres-Jorge Stephan, Ferre Mariana, Rodríguez-Martinó Esteban, Torres Esther A, Sariol Carlos A
Gastroenterology Research, School of Medicine, University of Puerto Rico, San Juan 00925, Puerto Rico.
Department of Microbiology and Medical Zoology, School of Medicine, University of Puerto Rico, San Juan 00925, Puerto Rico.
Vaccines (Basel). 2022 Aug 11;10(8):1301. doi: 10.3390/vaccines10081301.
Management of inflammatory bowel disease (IBD) often relies on biological and immunomodulatory agents for remission through immunosuppression, raising concerns regarding the SARS-CoV-2 vaccine's effectiveness. The emergent variants have hindered the vaccine neutralization capacity, and whether the third vaccine dose can neutralize SARS-CoV-2 variants in this population remains unknown. This study aims to evaluate the humoral response of SARS-CoV-2 variants in patients with IBD 60 days after the third vaccine dose [BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)]. Fifty-six subjects with IBD and 12 healthy subjects were recruited. Ninety percent of patients with IBD (49/56) received biologics and/or immunomodulatory therapy. Twenty-four subjects with IBD did not develop effective neutralizing capability against the Omicron variant. Seventy percent (17/24) of those subjects received anti-tumor necrosis factor therapy [10 = adalimumab, 7 = infliximab], two of which had a history of COVID-19 infection, and one subject did not develop immune neutralization against three other variants: Gamma, Epsilon, and Kappa. All subjects in the control group developed detectable antibodies and effective neutralization against all seven SARS-CoV-2 variants. Our study shows that patients with IBD might not be protected against SARS-CoV-2 variants, and more extensive studies are needed to evaluate optimal immunity.
炎症性肠病（IBD）的治疗通常依赖生物制剂和免疫调节药物通过免疫抑制来实现缓解，这引发了人们对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗有效性的担忧。新出现的变异株阻碍了疫苗的中和能力，而第三剂疫苗是否能中和该人群中的SARS-CoV-2变异株仍不清楚。本研究旨在评估接受第三剂疫苗[BNT162b2（辉瑞-BioNTech）或mRNA-1273（莫德纳）]60天后IBD患者对SARS-CoV-2变异株的体液反应。招募了56名IBD患者和12名健康受试者。90%的IBD患者（49/56）接受了生物制剂和/或免疫调节治疗。24名IBD患者未产生针对奥密克戎变异株的有效中和能力。这些受试者中有70%（17/24）接受了抗肿瘤坏死因子治疗[10例使用阿达木单抗，7例使用英夫利昔单抗]，其中2例有新冠病毒感染史，1名受试者对其他三种变异株：伽马、埃普西隆和卡帕未产生免疫中和作用。对照组的所有受试者均产生了可检测到的抗体，并对所有七种SARS-CoV-2变异株具有有效的中和作用。我们的研究表明，IBD患者可能无法抵御SARS-CoV-2变异株，需要进行更广泛的研究来评估最佳免疫情况。
